CDKN2A and neoplasm: Horbinski et al. found that palbociclib decreased tumor cell viability in vitro and improved survival in vivo when combined with RT for targeting p16-deficient (CDKN2A deleted) CH157 and IOMM-LEE cells but were ineffective for p16-intact and Rb-deficient meningiomas [54].